EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CALB1 expression in meningioma: associations with progression-free survival and chromosome arm 6q loss

Lukas S Friedrich iD, Friederike Liesche-Starnecker, Philipp Sievers, Claire Ertelt-Delbridge, Katharina J Weber, Daniel Schrimpf, Nicole Pfarr, Patrick N Harter, Jürgen Schlegel, Michael Meyer

Acta Neuropathologica · 05.11.2026 · 152 (1)

DOI: 10.1007/s00401-026-03113-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 05.11.2026. Verfasst von Lukas S Friedrich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physiology, Biomedical Center, LMU Munich, 80336, Munich, Germany. Lukas.Friedrich@med.uni-heidelberg.de. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Calbindin 1, Chromosomes, Human, Pair 6. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Faculty at the LMU Munich, Ludwig-Maximilians-Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular profiling has refined risk stratification in meningioma, but the biological relevance of associated transcriptional changes remains incompletely understood. Calbindin D28K (Calb), encoded by CALB1 , is a calcium-binding protein with reported anti-apoptotic and cytoprotective functions. Previous unsupervised transcriptomic analysis identified CALB1 upregulation in meningiomas with aggressive cellular features, but its biological and clinical relevance remains unresolved. We analysed Calb immunoreactivity in 231 meningioma tissue microarray (TMA) cores from 147 patients and evaluated CALB1 transcript expression, DNA methylation and copy-number alterations in an independent cohort of 110 primary meningiomas. Calb immunoreactivity was detected in approximately 30% of primary tumours, and elevated CALB1 transcript levels were observed at a similar frequency in the molecular cohort. High Calb protein expression was associated with shorter progression-free survival (PFS) after adjustment for the included clinical variables in the primary cohort. This association was also observed in restricted analyses of histological WHO grade 2 meningiomas. Lower methylation of selected exonic and intronic CALB1 CpG sites correlated with a higher transcript expression, consistent with an epigenetic contribution to deregulation. Multivariable analyses identified associations of CALB1 transcript expression with chromosome arm 6q loss, histological WHO grade, CALB1 hypo-methylation and specific methylation subclasses in the secondary cohort. Differential expression analysis of tumours harbouring 6q loss identified expression differences in CALB1 and transcription factors, including NKX2-5 and SOX11 . In contrast, expression of a related calcium-binding protein Calretinin (Calr) and the Progesterone Receptor (PR) was not significantly associated with PFS in the primary cohort. Together, these findings support the potential prognostic relevance of Calb protein expression, particularly in histological WHO grade 2 meningiomas, and associate CALB1 transcript expression with selected molecular features in complementary cohorts. Calb immunohistochemistry may therefore provide a practical tool for refining risk stratification in this clinically heterogeneous tumour type prior to integrative molecular testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsCalbindin 1Chromosomes, Human, Pair 6HumansFemaleMaleDNA MethylationMiddle AgedProgression-Free SurvivalAgedAdultChromosome DeletionAged, 80 and overBiomarkers, Tumor

Stichwörter der Autor:innen

CALB16q lossCalbindinCalretininMeningioma

Substanzen

Calbindin 1CALB1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Institute of Physiology, Biomedical Center, LMU Munich, 80336, Munich, Germany. Lukas.Friedrich@med.uni-heidelberg.de.
  • Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, 69120, Heidelberg, Germany. Lukas.Friedrich@med.uni-heidelberg.de.
  • Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), 69120, Heidelberg, Germany. Lukas.Friedrich@med.uni-heidelberg.de.
  • Institute of Neuropathology, Faculty of Medicine, Ulm University Center, Ulm University, 89081, Ulm, Germany.
  • Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, 69120, Heidelberg, Germany.
  • Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), 69120, Heidelberg, Germany.

ORCID-Profile: Lukas S Friedrich

Förderung

  • Medical Faculty at the LMU Munich
  • Ludwig-Maximilians-Universität München

Zitieren

APA

Friedrich, L. S., Liesche-Starnecker, F., Sievers, P., Ertelt-Delbridge, C., Weber, K. J., Schrimpf, D., Pfarr, N., Harter, P. N., Schlegel, J., & Meyer, M. (2026). CALB1 expression in meningioma: associations with progression-free survival and chromosome arm 6q loss. Acta Neuropathologica, 152(1). https://doi.org/10.1007/s00401-026-03113-3

Vancouver

Friedrich LS, Liesche-Starnecker F, Sievers P, Ertelt-Delbridge C, Weber KJ, Schrimpf D, et al. CALB1 expression in meningioma: associations with progression-free survival and chromosome arm 6q loss. Acta Neuropathologica. 2026;152(1). doi:10.1007/s00401-026-03113-3

BibTeX
@article{Friedrich2026,
  author = {Friedrich, Lukas S and Liesche-Starnecker, Friederike and Sievers, Philipp and Ertelt-Delbridge, Claire and Weber, Katharina J and Schrimpf, Daniel and Pfarr, Nicole and Harter, Patrick N and Schlegel, Jürgen and Meyer, Michael},
  title = {CALB1 expression in meningioma: associations with progression-free survival and chromosome arm 6q loss},
  journal = {Acta Neuropathologica},
  year = {2026},
  volume = {152},
  number = {1},
  doi = {10.1007/s00401-026-03113-3}
}
Kostenlos starten →